Company intelligence / Profile preview
BiomeBank
Adelaide, South Australia, Australiabiomebank.com ↗
- Ownership
- Private
- Employees
- ~22
- Development stage
- Commercial
01
Overview
BiomeBank has achieved the world’s first regulatory approval for a donor-derived microbiome therapy to treat recurrent/refractory C. diff infection in Australia. Its next-generation cultured consortia therapies are advancing through preclinical and early clinical development targeting IBDs like ulcerative colitis and Crohn's disease.
- Therapeutic areas
- GastroenterologyInfectious Diseases
- Modalities
- Cultured microbial consortia (synthetic microbiota)Donor-derived microbiota (FMT)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
RMIT UniversityHudson Institute of Medical ResearchSt Vincent’s Hospital MelbourneThe Queen Elizabeth Hospital Adelaidepartnership with Cytiva for scale-up/manufacturing support.
Beyond the preview
Go deeper on BiomeBank.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BiomeBank.